Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Combined With DAPT After Drug-Coated Balloon Angioplasty in ACS
NCT05750758Completed
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of rivaroxaban in acute coronary syndrome (ACS) (2 arms), sponsored by Henan Institute of Cardiovascular Epidemiology. Primary endpoint: Late Lumen Loss at 6 months. Started Feb 2023; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05750758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750758.